Gallen International Conference 2011 proposed that breast cancer positive for ER and/or PgR, negative for HER2 with a Ki67 labeling index of less than 14%, should be defined as luminal A breast cancer [19]. This evidence concerns the gene ERBB2 and breast cancer.